Detailed Coverage

Parmax Pharma Ltd Announces Open Offer Post Share Acquisition

The open offer for Parmax Pharma Ltd shares is priced at ₹42.80 per share, involving 23,46,250 shares representing 26% of the expanded capital.
The maximum consideration for the offer is ₹10.04 crore, with an escrow amount of ₹5.20 crore.

Reader Takeaway: Open offer provides exit; new management targets API growth amidst persistent losses and compliance concerns.

What just happened

Parmax Pharma Ltd is subject to an open offer triggered by a substantial share acquisition through a Share Purchase Agreement and a proposed preferential issue. Dhiren Chandulal Shah and Sunil Chinubhai Shah are the identified acquirers.

Why this matters

This event signifies a change in control at Parmax Pharma. The open offer provides an exit route for existing public shareholders at a fixed price. The new management's success hinges on revitalizing the API and drug intermediate manufacturing business while addressing the company's financial and compliance challenges.

The backstory

The company has reported consistent losses over the last three fiscal years, with revenues fluctuating. For FY 2026, projected revenue is ₹12.11 crore with a loss of ₹4.16 crore. FY 2025 saw revenue of ₹28.20 crore and a loss of ₹2.09 crore, while FY 2024 reported ₹11.05 crore in revenue and a loss of ₹5.75 crore.

What changes now

With the completion of the transaction, the existing promoters will cease to hold that status and will be declassified. The new management, led by the acquirers, plans to focus on growing the existing business of manufacturing Active Pharmaceutical Ingredients (APIs) and drug intermediates and exploring related activities.

Risks to watch

Parmax Pharma has a history of regulatory non-compliance, including late disclosures, delayed filings, and audit qualifications. Fines have been levied by BSE for various violations. Qualified audit opinions were noted for FY 2024-25 and the quarter ended June 2025, indicating ongoing concerns.

Peer comparison

No direct peer comparison information is available in the provided filing text.

Context metrics (time-bound)

• Revenue from Operations: FY 2024: ₹11.05 crore, FY 2025: ₹28.20 crore, FY 2026 (projected): ₹12.11 crore.
• Profit / (Loss) After Tax: FY 2024: ₹(5.75) crore, FY 2025: ₹(2.09) crore, FY 2026 (projected): ₹(4.16) crore.

What to track next

Investors should carefully evaluate the open offer document, compare the offer price to their acquisition cost, and consider the future potential under new management. Monitoring the company's ability to improve compliance, reduce losses, and execute its growth strategy in API manufacturing will be crucial.